Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Gilead Sciences Inc.’s stock climbed 3% early Thursday after the company said its twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, building the case for ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences rose 2% in early trading, after the biotech reported positive data for a long-acting HIV prevention drug that promises to be a big seller. The drug, called lenacapavir, was 96% ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $95.00.

NDAQ:GILD) Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies ...

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...

High-rolling investors have positioned themselves bullish on Gilead Sciences (NASDAQ:GILD), and it's important for retail traders to take note. \This activity came to our attention today through ...

NORTHAMPTON, MA / ACCESSWIRE / September 10, 2024 / This year, we're among 42 organizations being recognized by Seramount as ...